(CTMX) – Analyzing CytomX Therapeutics’s Short Interest
CytomX Therapeutics’s (NYSE:CTMX) short percent of float has risen 143.23% since its last report. The company recently reported…
Analysts’ Varied Perspectives On CytomX’s CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer
Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.
Gold Moves Higher; Roblox Issues Weak Outlook
U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping over 200 points…
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Shares of Duolingo, Inc. (NASDAQ:DUOL) fell sharply during Thursday’s session after the company reported first quarter financial results.…
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Embecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday’s regular session. The company’s market cap stands…
Dow Jumps Over 150 Points; US Foods Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Thursday.…
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in today’s pre-market trading after the company reported better-than-expected first-quarter financial…
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Zai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday’s pre-market session. The market value of…
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers CytomX Therapeutics (NASDAQ:CTMX) stock increased by 87.1% to $7.84 during Wednesday’s after-market session. The market value of…
CytomX Therapeutics Announces Clinical Collaboration With Merck To Evaluate CX-801 In Combination With KEYTRUDA
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform